• Julia Edward, Fidaa Al-Shakfa, Nicholas Newman, and Frédéric Lavoie.
• CHUM Research Centre, Centre de Recherche du Centre Hospitalier de l'Universite de Montreal, 1000, rue St- Denis, Montréal, Québec, H2X 0C1, Canada. julia.edward@umontreal.ca.
• Arch Orthop Trauma Surg. 2024 Jul 1; 144 (7): 301730243017-3024.

IntroductionHigh tibial osteotomy (HTO) is a surgery performed to treat the symptoms and prevent the progression of medial osteoarthritis. Post-operative bleeding has led to early returns to hospital following surgery. Intrafocal injection of tranexamic acid (TXA) could reduce this bleeding complication. The objective of the study was to evaluate the effect of TXA during HTO on the incidence of post-operative complications and early returns to hospital.Materials And MethodsThis retrospective study included 251 cases of HTO performed between May 2012 and October 2021, with the use of TXA introduced in May 2017. The experimental (n = 102) and control (n = 149) groups were compared as to the rate of post-operative early returns. The influence of confounding factors was evaluated, including age, sex, body mass index (BMI), tobacco use, grade of medial femorotibial osteoarthritis (MFTO), magnitude of angular correction (MAC), and surgery duration.ResultsNo statistically significant difference was found between the groups with regards to all variables except age. The experimental group was significantly older (54.4 years; σ = 7.5) than the control group (50.4 years; σ = 7.9; p < 0.001). We observed a decrease in emergency department (ED) visits in the experimental group (15.7%) compared to the control (30.2%; p = 0.008) and a decrease in early returns in the experimental group (28.4%) compared to the control (40.5%; p = 0.049). No statistically significant difference in demographic data, MFTO, or MAC was found among patients with and without an early return, in both the experimental and control groups.ConclusionThe intrafocal injection of TXA during HTO decreases early returns to hospital.© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

27 keywords...

hide…